2:41 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Company News

Keytruda wins another FDA approval

Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat primary mediastinal large B cell lymphoma in patients who have relapsed after two or more prior lines of therapy. The pharma said Keytruda is the first PD-1 inhibitor approved to treat PMBCL.

On Tuesday, Merck said Keytruda became the first PD-1 inhibitor approved to treat advanced cervical cancer.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD